Imagine Institute and GlaxoSmithKline (GSK) Agree on a Collaborative Partnership for Drug Discovery for rare diseases
November 12th, 2012, Paris (France) – GlaxoSmithKline (GSK) and Imagine Institute (the newly established University Hospital Institute dedicated to Orphan and Paediatric diseases – Inserm/ University Paris Descartes) have agreed a collaborative partnership to discover and develop medicines with the potential to treat Netherton Syndrome, a rare, genetically inherited, severe skin disorder.
Under the terms of the agreement initiated and brokered by Inserm Transfert, the alliance will seek to build on the work of Prof. Alain Hovnanian at the Necker Children Hospital in Paris following significant breakthroughs in the understanding of the underlying disease mechanisms guided by the identification of the disease gene. Work on the project will be carried out within GSK and both at the Genetics Department and Inserm unit U781, Necker Hospital, Paris. The collaboration will operate as a single integrated team, combining Prof. Hovnanian’s deep disease and biology understanding with GSK’s expertise in drug discovery and development.